The COVID-19 pandemic that hit the world in 2020 triggered a massive dissemination of information (“infodemic”) about the disease channeled through the web and social media. This “infodemic” included also sensational and distorted information about drugs, which likely affected primarily opinion leaders and people particularly active on social media, and subsequently other peoples leading to inadequate choices by individual patients everywhere. In particular, for some drugs approved with other indications, namely chloroquine, hydroxychloroquine, NSAIDs, ACE inhibitors, angiotensin II receptor antagonists, favipiravir and umifenovir, information has spread that has led to a hazardous use. In this article, we analyzed the rationale behind the claim for use of these drugs in COVID-19, the communication about their effect on the disease, the consequences of this communication on people's behavior and the response of some influential regulatory authorities in an attempt to minimize the actual or potential risks arising from this behavior. Finally, we discussed the role of pharmacovigilance stakeholders in emergency management and possible strategies to be put in place to deal with other similar situations in the future.